Stocks to Watch: Gemini Explorations, Inc. (OTCBB: GXPI), NutraCea (OTC BB:NTRZ), Hythiam, Inc. (NasdaqGM:HYTM),
Featured Stock: Gemini Explorations, Inc.
(OTCBB: GXPI)
Current Price (0.20)
GEMINI EXPLORATIONS INC PROVIDES SECOND PAYMENT TO ACQUIRE THE LOS CHORROS GOLD MINE
~Los Chorros Gold Mine: a producing gold project in Antioquia,
Calgary, AB -- November 7, 2007-- Gemini Explorations Inc, (“Gemini”) OTCBB: GXPI, is pleased to announce that it has executed the second payment of US$40,000 as outlined in the definitive agreement to acquire the Los Chorros Gold Mine, a producing gold property in the El Bagre-Zargoza mining district, department of Antioquia, Colombia. Gemini has acquired an 80 percent majority controlling interest in the property for the sum of U$100,000 and the issuance of 2,500,000 restricted shares of GXPI. The company has paid US$50,000 to date in two separate payments leaving US$50,000 to complete the acquisition. Gemini has first right of refusal to acquire the remaining 20 % interest in the mine within 18 months of the Effective Date.
The Los Chorros Mine is currently being mined with extremely antiquated equipment and Gemini believes that the project could be turned into a highly efficient producing gold project with low capital costs. Current mining operations at Los Chorros recover a low percentage of the available gold and precious metals present on the property. The plant would initially run at 30 to 50 tonnes/day with a targeted production rate of 100 tonnes per day during the first year. Gemini reported on November 5, 2007 that a 100 tonne per day production rate would produce US$1,080,280 monthly and over US$12,900,000 annually. These estimates are based on US$730 per ounce gold with US$200 per ounce operating and production costs netting US$530 per ounce.
The total cost of the project is estimated to be US$595,900, adding a contingency factor of 30% would bring the maximum projected total to US$774,700.The reports were prepared by general manager Juan Fernando Restrepo and chief geologist Carlos Alberto Vera of Minera Primecap Geological Services (MPGS) of
Historically one of the largest gold producing countries in the world,
Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the expectation of the gold production of the property to be acquired, the low capital costs to upgrade the Los Chorros operating plant, the assumed production and net cash flow.Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the 2006 fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Michael Hill
President
Gemini Explorations, Inc
http://www.geminiexploration.com/ email: info@geminiexploration.com
IR info: 1 877 700 1644
For an in-depth analyst report, please visit: www.WallstreetStockReview.com
NutraCea
(OTC BB:NTRZ)
Current Price (1.40)
PHOENIX, Nov. 6 -- NutraCea (OTC Bulletin Board: NTRZ - News), a health science company and a world leader in stabilized rice bran (SRB), announced today that the construction of its Southern Louisiana facility at Lake Charles is on track to be completed and commissioned by the end of March 2008. NutraCea is a leader in stabilized rice bran nutrient research and dietary supplement development. Through its wholly owned subsidiary RiceX, the company manufacturers as well as distributes products and food ingredients made from Rice Bran through its proprietary technology and processes. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health- promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.nutracea.com/.
Hythiam, Inc.
(NasdaqGM:HYTM)
Current Price (4.70)
LOS ANGELES--Nov. 5--Hythiam, Inc. (NASDAQ:HYTM - News) today announced that the Russian Patent Office has informed Hythiam of their decision to grant Hythiam’s patent for the use of a composition of matter for the treatment of cocaine dependency. The patent will serve to enhance protection of the intellectual property underlying the company’s PROMETA® Treatment Program for cocaine dependence and follows the granting of cocaine patents in other major markets over the past 12 months, including the U.S., Europe, Japan, and Korea. The Russian Patent Office granted Hythiam a similar patent for the treatment of alcohol dependency in 2006. Hythiam, Inc. provides behavioral health management services to health plans, employers, criminal justice, and government agencies through a network of licensed and company managed providers. The company approaches the management of behavioral health disorders with a focus on using the latest medical and health technology towards improved outcomes and out-patient treatment. Hythiam also researches, develops, licenses and commercializes innovative and proprietary physiological, nutritional, and behavioral treatment programs. Hythiam offers disease management for substance dependence built around its proprietary PROMETA® Treatment Program for alcoholism and dependence to stimulants. The PROMETA® Treatment Program, which integrates behavioral, nutritional, and medical components, is available through both licensed treatment providers and company managed PROMETA® Centers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA® Treatment Program. For further information, please visit www.hythiam.com.
(OTC BB:NGLPF)
Current Price (1.29)
VANCOUVER, BC--Nov 6, 2007 -- Nevada Geothermal Power Inc. (NGP) (CDNX:NGP.V - News) (OTC BB:NGLPF.OB - News) today announced that its wholly owned and newly formed subsidiary NGP Blue Mountain I LLC ("NGP I") has closed a US$20MM Bridge Financing with Glitnir Banki hf ("Glitnir") and has amended/restated the Commitment Letter for the Construction Loan to include Glitnir as underwriter of the construction loan. Nevada Geothermal Power Inc. is a renewable energy company developing geothermal projects in the
Novacea, Inc.
(NasdaqGM:NOVC)
Current Price (2.86)
SOUTH SAN FRANCISCO, CA--Nov 5, 2007 -- Novacea, Inc. (NasdaqGM:NOVC - News) announced today that the company has ended its Phase 3 ASCENT-2 clinical trial of Asentar(TM) (DN-101), the company's lead investigational cancer therapy for the treatment of patients with androgen-independent prostate cancer, or AIPC, due to an imbalance of deaths between the two treatment arms, as observed by the Data Safety Monitoring Board (DSMB) for the clinical study. Asentar is an investigational new drug that is an oral, intermittent, high-dose of calcitriol, the most potent natural ligand or activator of the calcitriol receptor (also known as the vitamin D receptor). The Phase 3 ASCENT-2 study design was based on published results from a double-blinded, placebo-controlled, randomized, multi-site Phase 2 trial of Asentar plus Taxotere as compared to placebo plus Taxotere in AIPC. Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates in clinical trials, including Asentar(TM), which has been in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC, and in a Phase 2 trial for advanced pancreatic cancer. Asentar is part of a development and commercialization agreement with Schering-Plough Corporation. Novacea's second product candidate, AQ4N, is a hypoxia-activated prodrug that is currently in a Phase 1b/2a clinical trial in glioblastoma multiforme and a Phase 2 trial for refractory acute lymphoblastic leukemia. More information on any of Novacea's trials can be found at www.ClinicalTrials.gov.
WallStreetStockReview.com is owned and operated by Iron Consulting.
Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering secu rities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
